More importantly, TSP4 levels in CSF increased in pediatric SMA patients after the first dose of Nusinersen, suggesting that TSP4 has the potential to be a biomarker for monitoring treatment response in pediatric SMA patients. The gene discussed is THBS4; the disease is proximal spinal muscular atrophy.